Subtopic Deep Dive
PARP Inhibitor Therapy Ovarian Cancer
Research Guide
What is PARP Inhibitor Therapy Ovarian Cancer?
PARP inhibitor therapy in ovarian cancer uses drugs like olaparib, niraparib, and rucaparib to target DNA repair deficiencies in BRCA-mutated and HRD-positive tumors, improving progression-free survival as maintenance treatment.
Clinical trials demonstrate PARP inhibitors extend progression-free survival in newly diagnosed and recurrent ovarian cancer, particularly in BRCA1/2 mutation carriers (Moore et al., 2018; 2683 citations). Niraparib benefits patients regardless of BRCA status (Mirza et al., 2016; 2356 citations), while combinations like olaparib with bevacizumab enhance outcomes in HRD-positive cases (Ray-Coquard et al., 2019; 1893 citations). Over 15 key trials since 2011 validate biomarker-stratified efficacy.
Why It Matters
PARP inhibitors enable precision medicine in ovarian cancer by exploiting synthetic lethality in HR-deficient tumors, leading to FDA approvals for maintenance therapy post-platinum response. Moore et al. (2018) showed 70% reduced progression risk in BRCA-mutated advanced cases, transforming first-line treatment. Ray-Coquard et al. (2019) confirmed benefits with bevacizumab combinations, while Swisher et al. (2016) validated rucaparib in relapsed platinum-sensitive disease, guiding patient selection via genomic profiling (Bell et al., 2011). This shifts ovarian cancer from uniform chemotherapy to targeted regimens, improving survival in 15-20% of high-grade serous cases with BRCAness.
Key Research Challenges
Resistance Development
Tumors evolve resistance to PARP inhibitors through BRCA reversion mutations or alternative DNA repair pathways. Swisher et al. (2016) observed variable responses in relapsed cases despite initial platinum sensitivity. Developing strategies to overcome resistance remains critical (Alsop et al., 2012).
Biomarker Identification
Accurately stratifying HRD-positive patients beyond BRCA1/2 mutations is challenging due to heterogeneous genomic loss-of-heterozygosity scores. Bell et al. (2011) cataloged aberrations but clinical assays vary. Trials like ARIEL2 highlight need for reliable HRD signatures (Swisher et al., 2016).
Combination Optimization
Integrating PARP inhibitors with anti-angiogenics or immunotherapy yields mixed PFS benefits across populations. Coleman et al. (2019) found veliparib maintenance inferior alone but promising in combos. Dosing and sequencing require further RCTs (Ray-Coquard et al., 2019).
Essential Papers
Integrated genomic analyses of ovarian carcinoma
Debra Bell, Andrew Berchuck, Michael J. Birrer et al. · 2011 · Nature · 7.9K citations
A catalogue of molecular aberrations that cause ovarian cancer is critical for developing and deploying therapies that will improve patients' lives. The Cancer Genome Atlas project has analysed mes...
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia et al. · 2018 · New England Journal of Medicine · 2.7K citations
The use of maintenance therapy with olaparib provided a substantial benefit with regard to progression-free survival among women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation,...
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt et al. · 2016 · New England Journal of Medicine · 2.4K citations
Among patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progression-free survival was significantly longer among those receiving niraparib than among those receivin...
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Isabelle Ray‐Coquard, Patricia Pautier, Sandro Pignata et al. · 2019 · New England Journal of Medicine · 1.9K citations
In patients with advanced ovarian cancer receiving first-line standard therapy including bevacizumab, the addition of maintenance olaparib provided a significant progression-free survival benefit, ...
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M. Swisher, Kevin Lin, Amit M. Oza et al. · 2016 · The Lancet Oncology · 1.2K citations
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
Kathryn Alsop, Sián Fereday, Cliff Meldrum et al. · 2012 · Journal of Clinical Oncology · 1.1K citations
Purpose The frequency of BRCA1 and BRCA2 germ-line mutations in women with ovarian cancer is unclear; reports vary from 3% to 27%. The impact of germ-line mutation on response requires further inve...
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
Nicoletta Colombo, Cristiana Sessa, Andreas du Bois et al. · 2019 · Annals of Oncology · 1.1K citations
Reading Guide
Foundational Papers
Start with Bell et al. (2011, 7936 citations) for TCGA genomic aberrations enabling PARPi targeting, then Alsop et al. (2012) for BRCA frequency/response data.
Recent Advances
Study Moore et al. (2018) for olaparib frontline efficacy, Ray-Coquard et al. (2019) for bevacizumab combos, and Swisher et al. (2016) for rucaparib in relapse.
Core Methods
Key techniques include genomic profiling for BRCA/HRD (Bell et al., 2011), progression-free survival as primary endpoint in phase 3 RCTs (Moore et al., 2018), and ARIEL models for biomarker stratification (Swisher et al., 2016).
How PapersFlow Helps You Research PARP Inhibitor Therapy Ovarian Cancer
Discover & Search
Research Agent uses searchPapers and exaSearch to find trials like 'Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer' (Moore et al., 2018), then citationGraph reveals 50+ related works on HRD biomarkers from Bell et al. (2011). findSimilarPapers expands to niraparib studies (Mirza et al., 2016), surfacing ARIEL2 trial (Swisher et al., 2016).
Analyze & Verify
Analysis Agent applies readPaperContent to extract survival data from Moore et al. (2018), then runPythonAnalysis with pandas computes hazard ratios across BRCA/HRD cohorts. verifyResponse (CoVe) with GRADE grading scores evidence as high-quality for PFS endpoints, verifying claims against Mirza et al. (2016) platinum-free interval stats.
Synthesize & Write
Synthesis Agent detects gaps in resistance mechanisms post-Swisher et al. (2016), flagging contradictions in veliparib efficacy (Coleman et al., 2019). Writing Agent uses latexEditText for trial comparison tables, latexSyncCitations for 20+ refs, and latexCompile for publication-ready reviews; exportMermaid diagrams HRD pathway vulnerabilities.
Use Cases
"Extract survival curves from olaparib and niraparib trials in BRCA ovarian cancer"
Research Agent → searchPapers → Analysis Agent → readPaperContent (Moore 2018, Mirza 2016) → runPythonAnalysis (NumPy/matplotlib plots Kaplan-Meier curves, HR comparisons) → researcher gets CSV of PFS data and overlaid survival graphs.
"Draft LaTeX review of PARP inhibitor combos in HRD ovarian cancer"
Synthesis Agent → gap detection (Ray-Coquard 2019) → Writing Agent → latexEditText (structure sections) → latexSyncCitations (15 papers) → latexCompile → researcher gets PDF manuscript with biomarker tables and synced refs.
"Find code for HRD genomic scoring from ovarian cancer papers"
Research Agent → paperExtractUrls (Bell 2011 TCGA) → paperFindGithubRepo → githubRepoInspect → researcher gets validated HRDscore Python repo with loss-of-heterozygosity calculator linked to Swisher 2016.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ PARP trials: searchPapers → citationGraph (Moore 2018 cluster) → GRADE all abstracts → structured report with PFS meta-table. DeepScan analyzes resistance in 7 steps: readPaperContent (Swisher 2016) → runPythonAnalysis reversion mutations → CoVe checkpoints. Theorizer generates hypotheses on next-gen PARPi from HRD gaps in Bell et al. (2011).
Frequently Asked Questions
What defines PARP inhibitor therapy in ovarian cancer?
PARP inhibitors like olaparib target HR-deficient tumors via synthetic lethality, approved for maintenance in BRCA-mutated advanced cases (Moore et al., 2018).
What are key methods in PARP trials?
Randomized phase 3 trials test maintenance post-platinum, using HRD scores and BRCA status for stratification (Mirza et al., 2016; Ray-Coquard et al., 2019).
What are seminal papers?
Moore et al. (2018, NEJM, 2683 citations) for olaparib PFS benefit; Mirza et al. (2016, 2356 citations) for niraparib; Bell et al. (2011, 7936 citations) for genomic basis.
What open problems exist?
Overcoming resistance via reversion mutations and optimizing non-BRCA HRD patient selection lack prospective validation (Swisher et al., 2016; Coleman et al., 2019).
Research Ovarian cancer diagnosis and treatment with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching PARP Inhibitor Therapy Ovarian Cancer with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.